PhaseBio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. Our lead product candidate is PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and our second product candidate is PB1046, a once-weekly fusion protein for the treatment of pulmonary arterial hypertension. PB1046 utilizes our proprietary elastin-like polypeptide (ELP) technology, which also serves as the engine for our preclinical pipeline.
Aug 7, 2020 5:37 AM EDT
Data Provided by Refinitiv. Minimum 15 minutes delayed.
We use essential cookies to make our site work. These enable core functionality such as security and accessibility. Essential cookies are on by default. You can disable these by changing your browser settings, but this may affect how the website functions.
Google Analytics Cookies
We would like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. These cookies collect information in a way that does not directly identify anyone.